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Abstract
Introduction: Triple-negative breast cancer (TNBC) high rate of relapse is thought to be due to the presence of
tumor-initiating cells (TICs), molecularly defined as being CD44high/CD24-/low. TICs are resilient to chemotherapy
and radiation. However, no currently accepted molecular target exists against TNBC and, moreover, TICs. Therefore,
we sought the identification of kinase targets that inhibit TNBC growth and eliminate TICs.
Methods: A genome-wide human kinase small interfering RNA (siRNA) library (691 kinases) was screened against
the TNBC cell line SUM149 for growth inhibition. Selected siRNAs were then tested on four different breast cancer
cell lines to confirm the spectrum of activity. Their effect on the CD44high subpopulation and sorted CD44high/
CD24-/low cells of SUM149 also was studied. Further studies were focused on polo-like kinase 1 (PLK1), including its
expression in breast cancer cell lines, effect on the CD44high/CD24-/low TIC subpopulation, growth inhibition,
mammosphere formation, and apoptosis, as well as the activity of the PLK1 inhibitor, BI 2536.
Results: Of the 85 kinases identified in the screen, 28 of them were further silenced by siRNAs on MDA-MB-231
(TNBC), BT474-M1 (ER+/HER2+, a metastatic variant), and HR5 (ER+/HER2+, a trastuzumab-resistant model) cells and
showed a broad spectrum of growth inhibition. Importantly, 12 of 28 kinases also reduced the CD44high
subpopulation compared with control in SUM149. Further tests of these 12 kinases directly on a sorted CD44high/
CD24-/low TIC subpopulation of SUM149 cells confirmed their effect. Blocking PLK1 had the greatest growth
inhibition on breast cancer cells and TICs by about 80% to 90% after 72 hours. PLK1 was universally expressed in
breast cancer cell lines, representing all of the breast cancer subtypes, and was positively correlated to CD44. The
PLK1 inhibitor BI 2536 showed similar effects on growth, mammosphere formation, and apoptosis as did PLK1
siRNAs. Finally, whereas paclitaxel, doxorubicin, and 5-fluorouracil enriched the CD44high/CD24-/low population
compared with control in SUM149, subsequent treatment with BI 2536 killed the emergent population, suggesting
that it could potentially be used to prevent relapse.
Conclusion: Inhibiting PLK1 with siRNA or BI 2536 blocked growth of TNBCs including the CD44high/CD24-/low TIC
subpopulation and mammosphere formation. Thus, PLK1 could be a potential therapeutic target for the treatment
of TNBC as well as other subtypes of breast cancer.
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Introduction
Triple-negative breast cancer (TNBC) is considered the
most aggressive breast cancer subtype because it is asso-
ciated with the greatest probability of early relapse and
death [1-3]. It is estimated that more than 1 million
women are diagnosed with breast cancer annually, and
TNBC accounts for about 15% of those cases [4]. They
are challenging clinically for a number of reasons. They
do not express the estrogen receptor (ER), progesterone
receptor, and human epidermal growth factor 2 (HER2).
Therefore, patients are not candidates for targeted agents,
such as antiestrogens and trastuzumab, that afford the
greatest survival benefit for eligible patients. The prog-
nosis for patients with this type of tumor is very poor,
not only because hormonal therapy and treatment with
trastuzumab are inapplicable, but also because these
tumors seem to be more aggressive than other breast
cancer subtypes [5].
Although it is highly sensitive to chemotherapy, the
progression-free time of TNBC, however, is generally
short, and has greater recurrence rates than those of
non-TNBC tumors during the first and third years after
their initial diagnosis, as well as a higher 5-year mortality
rate [3,4]. The high rates of early relapse indicate that the
tumor cells rapidly adapt to the insult of chemotherapy
by inducing resistance mechanisms. In addition, the
adverse side effects of traditional chemotherapy are inevi-
table for patients with TNBC, which leads to the notable
morbidity associated with treating this particular breast
cancer subtype. Thus, identifying specific molecular tar-
gets against TNBC is timely and essential.
No currently accepted therapeutic target is known for
TNBC, unlike some other subtypes of breast cancer [4].
ER-expressing breast tumors, for instance, can be treated
with tamoxifen and aromatase inhibitors, and HER2-
expressing ones can be treated with trastuzumab. Ongoing
studies are searching for new drug targets against TNBC.
One such development is the inhibition of poly (ADP-
ribose)-polymerase 1 (PARP1) [4,6]. PARP1 plays a vital
role in repairing DNA damage together with other
mechanisms that involve BRCA1 and BRCA2. The combi-
nation of the mutation of BRCA and PARP inhibition
attributed to so-called synthetic lethality [6,7]. The
impressive clinical phase II results involving these criteria
have led to a definitive phase III study [4]. Although this is
promising, BRCA1 and BRCA2 mutations account for
slightly more than 10% of breast cancers that are triple-
negative [8]. Other therapeutic targets under development
for TNBC include epidermal growth factor receptor
(EGFR), mammalian target of rapamycin (mTOR), the
RAS-mitogen-activated protein kinase signaling pathway
(Raf/Mek/MAP), and Src tyrosine kinase [4,9]. However,
some of these proposed targets are applicable only in
more-specific subgroups of TNBC, and the ways to tackle
the tumor-initiating subpopulation, which is believed to be
the root cause of the relapse of cancer, have not been fully
studied. For breast cancer, it has been proposed that the
subpopulation cells of CD44high/CD24-/low have cancer
stem cell properties [10,11]. Such cancer stem cells or
tumor-initiating cells (TICs) are resistant to traditional
chemotherapies and are considered to be responsible for
cancer relapse [10-13]. It has been reported that treatment
with traditional chemotherapies leads to enriched TICs
both in vitro and in vivo [14-17]. Thus targeting the bulk
cancer cell population, as well as TICs, should be consid-
ered at the early stage of the search for therapeutic targets.
Kinases play an essential role in the processes of pro-
tein phosphorylation and are deregulated in many dis-
eases, such as cancer. Numerous studies have proved
that many kinases are critical in cancer cell survival
under both in vitro and in vivo conditions [18-20].
Kinases are eminently the most treatable with drugs.
Some new drugs of kinase inhibitor, such as imatinib
(Gleevec), fasudil, and rapamycin, have been successfully
developed and applied clinically for treatment of a vari-
ety of cancers [21,22]. For TNBC, it has been shown
that several kinases could be targeted for growth inhibi-
tion, including MAP kinase, Src tyrosine kinase
(PDGFR, EGFR, IGF-1R, and HGFR), RSK kinases
[4,9,23,24]. More important, targeting kinases resulting
in growth inhibition of TICs of different cancers has
been reported [25,26]. Prochownik et al. [13,27] found
that CGP74514A and rottlerin, which are kinase inhibi-
tors of CDK1/cyclin B and PKC, respectively, can selec-
tively inhibit cancer stem cells isolated from the breast
cancer cell line MCF7. The availability of a large kinase
small interfering RNA (siRNA) library provides an excel-
lent tool for an unbiased genome-wide screen for active
kinases as potential therapeutic targets against not only
the bulk cancer cells but also TICs.
In this study, we first performed a genome-wide human
kinase siRNA library screen against a TNBC cell line
SUM149 for growth inhibition. A panel of selected active
kinases was then further tested on four different breast
cancer cell lines to confirm the spectrum of growth inhi-
bition. Several kinases that also inhibited the tumor-initi-
ating CD44high population in SUM149 after siRNA
treatments were identified and tested directly against
sorted CD44high/CD24-/low cells of SUM149. The most
impressive kinase lead was polo-like kinase 1 (PLK1).
Therefore, we focused on PLK1 inhibition as the best
potential therapeutic lead for TNBC by showing that it is
highly expressed in breast cancer cell lines, and its inhibi-
tion by PLK1 siRNA as well as BI 2536, an ATP-competi-
tive inhibitor designed to inhibit PLK1 [28], killed the
CD44high/CD24-/low population and induced apoptosis.
Hu et al. Breast Cancer Research 2012, 14:R22
http://breast-cancer-research.com/content/14/1/R22
Page 2 of 15
Combined treatment with drugs and BI 2536 greatly
inhibited the growth of TNBC. Therefore, it offers poten-
tial as a better therapeutic target for TNBC.
Materials and methods
Cell culture
SUM149 cells were purchased from Astrand (Ann Arbor,
MI, USA) and cultured in F-12 (Ham) media (Gibco/
Invitrogen, Burlington, ON, Canada) supplemented with
5 μg/ml insulin (Sigma-Aldrich, Oakville, ON, Canada),
1 μg/ml hydrocortisone (Sigma-Aldrich), 10 mM HEPES
(Sigma-Aldrich), and 5% fetal bovine serum (FBS; Gibco/
Invitrogen). MDA-MB-231 and MCF7 were purchased
from ATCC and cultured in Dulbecco Modified Eagle
medium (DMEM, Gibco/Invitrogen) with 10% FBS.
BT474-M1, a metastatic variant of BT474, was a gift of
Dr. Mien-Chie Hung (MD Anderson Cancer Center,
Houston, TX, USA). HR5, which is derived from BT474
and is resistant to trastuzumab, was from Dr. Carlos
Arteaga (Vanderbilt-Ingram Cancer Center, Nashville,
TN, USA). They were both cultured in DMEM-F12 (1:1)
with 10% FBS. AU565, HCC1937, and T47D (ATCC)
were cultured in RPMI-1640 media supplemented with
5% FBS (Gibco/Invitrogen), 10 mM HEPES, 4.5 g/L glu-
cose, 1 mM sodium pyruvate, and 100 units/ml penicil-
lin/streptomycin (Sigma-Aldrich). All the cells were
incubated at 37°C with 5% CO2, and subcultured twice
weekly during the experimental period.
Kinase siRNA library
The siRNA library (Vision 2) of 691 human kinases was
purchased from Qiagen (Toronto, ON, Canada). Two dif-
ferent sequences of siRNA target each of the genes in the
library. The siRNA stock samples were diluted to working
stocks at 2 μM on arrival by following the manufacturer’s
instructions and stored at -20°C before use.
Kinase siRNA library screen
The screening methods were previously described [19]. In
brief, SUM149 cells were seeded (5,000 cells/well) into 96-
well plates (BD; Becton Dickinson, Franklin Lakes, NJ,
USA) overnight. The cells were transfected with siRNA in
Lipofectamine RNAiMAX (Invitrogen) at 5 nM for
72 hours. Cells were then fixed in 2% paraformaldehyde
(Sigma-Aldrich) with nuclear dye, Hoechst 33342 (1 μg/
ml) (Sigma-Aldrich). After a gentle wash with phosphate-
buffered solution (PBS), the cells were kept in fresh PBS,
and the plates were kept at 4°C in the dark before analysis
on the ArrayScan high-content screening system (HCS;
Thermo Fisher Scientific, Pittsburgh, PA, USA). Twenty
view fields per well were scanned and analyzed. The
screen was repeated once to confirm the activity of siR-
NAs. Cells treated with Lipofectamine RNAiMAX alone
without siRNA served as controls. Additionally, scrambled
siRNAs and green fluorescent protein siRNAs, which were
included in the library, served as internal references in
each assay plate. Apoptosis was identified by nuclear mor-
phology and Hoechst dye intensity by the HCS system
[19], which allows simultaneously acquiring quantitative
cellular data and images of each individual cell sample.
Growth inhibition was calculated as a percentage of the
control. To focus on the most important kinases, only
those siRNAs that were active for both sequences and
showed a minimum of 30% inhibition compared with con-
trol were considered to be active in the screen.
Effect of the active kinases on the growth of different
breast cancer cell lines
A panel of 28 active kinases was selected from the hit list,
based on their activity and classes, and silenced by their
corresponding siRNAs in four breast cancer cell lines,
MDA-MB-231, SUM149, BT474-M1, and HR5. Cell lines
MDA-MB-231 and SUM149 are TNBC, whereas the latter
two are HER2 positive. Unless otherwise stated, all growth
assays in the study were done in replicates of three or five
and repeated at least once to confirm the activity.
Effect of the selected kinases on CD44 high subpopulation
of SUM149
SUM149 cells were treated with the selected siRNAs at
5 nM, as described in a previous section. After 72 hours of
treatment, the cells were fixed in 2% paraformaldehyde
with nuclear dye, Hoechst 33342, at room temperature for
30 minutes. The cells were then washed gently 3 times
with PBS and stained with 40 μl/well of mouse anti-
human CD44-PE conjugated antibody (BD Biosciences,
Mississauga, ON, Canada; 1:100 dilution) at room tem-
perature for 1 hour in the dark. The samples were then
washed with PBS and kept at 4°C in the dark before analy-
sis with the HCS system for the CD44high cells surviving
the siRNA treatments.
Effect of the selected kinases on sorted CD44high/CD24-/
low TIC subpopulation of SUM149
SUM149 cells were cultured and sorted for the
CD44high/CD24/-low subpopulation as described [14] to
test directly the effect of the active kinases on TICs.
Sorted cells were seeded at 5,000 cells/well into 96-well
culture plates (BD) and cultured overnight. The siRNAs
of the 12 selected kinases were then added as described
earlier. Cells treated with Lipofectamine RNAiMAX
alone without siRNA served as controls. Additionally,
scrambled siRNAs were included in the experiments,
and served as internal reference in each assay plate. The
treatment lasted for 72 hours. The treated cells were
then fixed and stained with Hoechst dye, and the
growth inhibition was analyzed with the HCS system, as
described in previous sections.
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PLK1 expression in different breast cancer cell lines and
its correlation to CD44
PLK1 protein expression in eight breast cancer cell lines,
SUM149, MDA-MB-231, BT474, HR5, HR6, MCF7,
HCC1937, and AU565, was investigated with Western
blot, as previously described [29]. In brief, proteins were
isolated from log-phase growing cells of these six cell lines
by using an ELB buffer [24]. PLK1 (Abcam, Cambridge,
MA, USA; 1:2,000 dilution) and actin (Cell Signaling, Pick-
ering, ON, Canada; 1:5,000 dilution) were detected with
immunoblotting.
To confirm the silencing efficacy of PLK1 siRNA on
PLK1 expression, SUM149 and MBA-MB-231 were
seeded into six-well culture plates (BD) at 350,000 cells/
well in 2 ml corresponding media. PLK1 and control siR-
NAs were added to achieve 5 nM final concentration, and
Lipofectamine RNAiMAX alone without siRNA served as
the control. The sample plate was then incubated for
72 hours. After harvesting the cells and extracting the pro-
teins, PLK1 expression was detected with immunoblotting
(1:2,000 for PLK1 and 1:5,000 for actin), as described
earlier.
To explore the possible connection between PLK1 and
CD44, SUM149 cells were seeded onto eight-chamber
slides (BD), washed with PBS, fixed with 2% formaldehyde
for 20 minutes, rinsed twice with PBS, and then incubated
with PBS containing 0.1% Triton X-100 (Sigma-Aldrich)
for 30 minutes. Next, the slides were washed with PBS and
incubated with mouse anti-CD44 (BD Biosciences; 1:200
dilution) and rabbit anti-PLK1 (LifeSpan Bioscience Inc.,
Seattle, WA, USA; 1:400 dilution) antibodies diluted in
buffer containing 10% bovine serum albumin and 2% goat
serum overnight at 4°C in a humidified container. After
washing 3 times with PBS, glass slides were incubated
with Alexa Fluor 546 anti-mouse and Alexa Fluor 488
anti-rabbit antibodies (Invitrogen; 1:1,000 dilution) for
1 hour, washed 3 times, and then mounted by using Pro-
long Gold (Invitrogen) with 4ʹ,6-diamidino-2-phenylin-
dole (DAPI; Invitrogen). Cells were observed with a Zeiss
AX10 microscope and photographed by using an Olympus
DP72 digital camera. All cells in three randomly selected
view fields (×10 magnification) were surveyed for CD44
and PLK1 expression, and the percentage of CD44high cells
that were also PLK1high was calculated.
PLK1 activity after inhibition by BI 2536 (a known PLK1
small-molecular inhibitor)
The effect of PLK1 inhibitor on PLK1 activity was studied
with an immunofluorescence method. SUM149 cells were
seeded on glass coverslips in six-well dishes and treated
with dimethyl sulfoxide (DMSO) or BI 2536 at 25 nM or
100 nM for 72 hours. Fixed cells were then stained with
rabbit anti-phospho-cyclin B1 (S133) (Cell Signaling; 1:200
dilution), which is a known downstream substrate of PLK1
[26]. This was followed by secondary antibody and image
acquisition, as described earlier.
For quantitative analysis of PLK1 activity, SUM149 cells
were seeded at 3,000 cells/well overnight and treated with
DMSO or BI 2536 at 10 to 100 nM in 96-well plates for
72 hours. Fixed cells were then stained with the cyclin B1
antibody, as described earlier, except that Hoechst was
used, and the cells were kept in PBS before analyzing with
the HCS system.
Growth inhibition of BI 2536 on different breast cancer
cells and TICs
Prior studies reported that BI 2536 is highly selective for
PLK1 when tested against 1,000 related kinases [28]. BI
2536 (Sigma-Aldrich) was prepared in DMSO and tested
against seven cell lines, SUM149, MDA-MB-231, BT474-
M1, HR5, MCF7, AU565, and T47D. Each cell line was
seeded at 3,000 cells/well and incubated overnight. Cells
were then treated with BI 2536 at concentrations of 1 to
100 nM in the medium for 72 hours. Propidium iodide
(PI, Sigma-Aldrich) and Hoechst dye solution were added
40 minutes before the end of treatments to each well at a
final concentration of 1 μg/ml for each dye. The sample
plates were then scanned live with the HCS system.
Growth inhibition was calculated as a percentage of the
control without the DMSO and the drug, and the samples
treated with DMSO alone served as a reference. To
address whether a longer period of treatment would
increase the efficacy of the drug compound, SUM149 cells
were treated with BI 2536 for 10 days. The methods were
the same as stated earlier, except that the seeding density
was only 1,000 cells/well, and the media with BI 2536
were later replaced with fresh media containing BI 2536 at
days 4 and 7 of the treatments.
To determine whether BI 2536 has a similar inhibitory
effect on TICs as do the PLK1 siRNAs, sorted CD44high/
CD24-/low cells of SUM149 were seeded at a density of
3,000 cells/well in 96-well plates. They were then treated
with BI 2536 at concentrations ranging from 1 to 100 nM
for 72 hours.
Mammosphere assays were performed with SUM149, as
well as with MDA-MB-231 cells, which highly expresses
CD44 in about 90% of its population, in ultra-low attach-
ment six-well culture plates (Corning, Lowell, MA, USA)
in complete Mammocult media (StemCell Technologies,
Vancouver, BC, Canada), as previously described [30].
DMSO control or BI 2536 (10 nM or 25 nM) was added
at time of seeding (5,000 cells/well). Serial passaging was
performed as per Subculture of Mammospheres protocol
(StemCell Technologies). In brief, after 7 days in culture,
mammospheres were counted, collected in a conical tube,
and centrifuged at 350 g for 5 minutes. Pellets were tritu-
rated with trypsin-EDTA (Invitrogen) to break up mam-
mospheres to single cells. Cold PBS with 2% FBS was
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added, and cells were centrifuged at 350 g for 5 minutes.
Pellets were resuspended in Mammocult media, and cell
counts were performed. The mammosphere assay was
reseeded by using the same cell densities and treatments
as described earlier.
Chemotherapeutic drugs like paclitaxel (Taxol), doxoru-
bicin (Dox), and 5-fluorouracil (5FU) had been reported to
induce resistance of cancer cells, and to this is probably
attributed their induction of TICs in the surviving popula-
tion [14,15,31,32]. To determine whether drug treatment
followed by BI 2536 could overcome the TICs, character-
ized as CD44high/CD24-/low, SUM149 cells were seeded at
1,000 cells/well in 96-well plates overnight. Taxol, Dox, or
5FU (Sigma-Aldrich) at different concentrations were then
added the following day, and the plates were incubated for
72 hours. One of the plates was then fixed and stained for
Hoechst, CD44 APC (BD Biosciences; 1:50 dilution) and
CD24 FITC (BD Biosciences; 1:10 dilution) antibodies, as
described earlier, and analyzed with an HCS system for
growth and CD44high/CD24-/low cells. The medium in the
second plate was removed and washed once with fresh
medium. Then the medium with BI 2536 at different con-
centrations was added to the plate and incubated for
another 4 days. The plate was fixed and analyzed with
HCS, as described.
Detection of apoptosis caused by BI 2536 on different
breast cancer cell lines
To investigate apoptosis caused by BI 2536 on breast can-
cer cells of SUM149, MDA-MB-231, BT474-M1, and HR5,
the cells after drug treatment were stained with PI or phos-
pho-H2AX for quantification of apoptosis [14,19]. In brief,
PI and Hoechst were added to cell wells at a final concen-
tration of 1 μg/ml each, 40 minutes before the end of the
72-hour treatments. The sample plates were then scanned
live with the HCS system. For phospho-H2AX, which is an
early indicator of apoptosis [14,19], treated cells were fixed
with 2% paraformaldehyde and Hoechst dye for 30 minutes
followed by permeabilization with Triton X-100 (Fisher
Scientific, Nepean, ON, Canada) and blocking with bovine
serum albumin (Sigma-Aldrich) [19]. They were then incu-
bated with mouse anti-human phospho-H2AX (Abcom;
1:100 dilution) for 1 hour at room temperature. This was
followed by rabbit anti-mouse Alexa Fluor 488 antibody
(Invitrogen; 1:100 dilution). The cells were gently washed
with PBS after each procedure. The sample plates were
finally analyzed, and images were taken by the HCS system.
Results
The siRNA library screen identified active kinases that
significantly inhibited the growth of TNBC cell line
SUM149
In the initial screen, 85 of the 691 kinases in total were
identified to be significantly growth inhibitory (> 30%
growth inhibition) on SUM149 cells once they were
silenced by 5 nM siRNAs for 72 hours under the experi-
mental conditions (Table 1; Table 1 of Additional file 1).
These active kinases (about 12.3% of the kinome library
tested) comprised a wide range of classes and functional
groups, indicating that the cancer cell growth could be
regulated through multiple genes and pathways. Of sig-
nificant importance are the cell cycle-related kinases,
MAP kinases, and protein kinases, as many identified
active kinases belong to these groups. The critical roles
they played in SUM149 cell growth and the strong sen-
sitivity to siRNA silencing indicate their potential as
therapeutic targets for TNBC. PLK1, in particular, is one
of the most active kinases identified in the screen. The
growth inhibition on SUM149 is more than 80%, with
significant apoptosis of the cells under the experimental
conditions.
The active kinases showed a broad spectrum of growth
inhibition on different breast cancer cell lines
Although the initial kinase siRNA library screen was
done on SUM149 cells, most of the 28 selected active
kinases, once silenced by their corresponding siRNAs,
showed a strong and broad spectrum of inhibitory effect
on the growth of all four cell lines tested, SUM149,
MDA-MB-231, BT474-M1, and HR5 (Figure 1). A few
examples of such kinases are PLK1, GCK, SKP2, PLAU,
RPS6KA2, PI4K2B, and LOC392265. In particular, these
kinases are significantly active on HR5, a trastuzumab-
resistant model. The results indicated that these kinases
offer potential applications not only in TNBC but also
in other subtypes of breast cancer.
The active kinases reduced the CD44high subpopulation
and inhibited the growth of sorted CD44high/CD24-/low
cells of SUM149 after siRNA knockdown
SUM149 cells consist of about 5% CD44high cells under
normal culture conditions. Of the 28 kinases tested, about
half of them significantly reduced the number of CD44high
in the surviving population of SUM149 after siRNA treat-
ments compared with the control (Figure 2A). In particu-
lar, 12 kinases, CSNK2A2, GCK, MAP3K4, PDGFRA,
PIK3C2G, PLAU, PLK1, SKP2, RPS6KA2, IHPK1, MAP-
K8IP3, and UCK1, are the most active ones. It is noted
also that deoxyguanosine kinase (DGUOK), conversely,
significantly induced CD44high cells after siRNA silencing.
When these 12 kinases were tested directly on TICs of
sorted CD44high/CD24-/low cells of SUM149 by silencing
them with corresponding siRNAs at 5 nM for 72 hours,
all of them, as expected, significantly inhibited the growth
of the TICs compared with control (Figure 2B). The
results confirmed our earlier observation of the reduced
number of CD44high cell in SUM149 after siRNA
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treatments of these 12 kinases (Figure 2A). PLK1, once
again, had the most significant inhibitory effect on TICs.
PLK1 is commonly expressed in breast cancer cells, and
its expression is correlated positively to CD44
Analysis with Western blot confirmed that PLK1 is com-
monly expressed in all eight breast cancer cell lines tested
(Figure 3A). In particular, SUM149, MDA-MB-231, and
HCC1937 are TNBC. Also, a siRNA silencing experiment
confirmed the specific knockdown of PLK1 in both
SUM149 and MDB-MB-231 cell lines (Figure 3B).
PLK1 is known to be highly associated with cell prolif-
eration [28,31]. We therefore addressed whether it
resides within the CD44high subpopulation. By immuno-
fluorescence, PLK1 was positively correlated to the
expression of CD44, in that most (89% ± 14%) of
CD44high cells were also PLK1high, whereas the CD44low
cells failed to express high levels of PLK1 (Figure 3C).
The high PLK1 in CD44high cells may help maintain TICs
and the ongoing proliferation of the tumor-initiating
population. The results could partially explain our obser-
vation that the CD44high subpopulation of SUM149 grew
faster than did CD44-/low cells (unpublished data).
BI 2536 inhibited PLK1 activity, which led to the
accumulation of phospho-cyclin B1 in SUM149 cells
Both qualitative and quantitative studies showed that PLK1
inhibition by BI 2536 at 25 nM or higher concentrations
led to aberrant accumulation of phospho-cyclin B1 in the
nuclear area of SUM149 cells (Figure 3D and 3E). The sig-
nificant accumulation started 24 hours after treatment with
100 nM but not 10 nM BI 2536 (data not shown).
Table 1 Partial list of the active kinases identified in the siRNA library screen
Accession
number
Symbol Brief description Growth
inhibition
(%)
NM-001786 CDC2 Cell-division cycle 2, G1 to S and G2 to M 68
a
NM-033487 CDC2L1 Cell-division cycle 2-like 1 (PITSLRE proteins) 71
NM-001274 CHEK1 CHK1 checkpoint homolog (S. pombe) 61
NM-001896 CSNK2A2 Casein kinase 2, alpha prime polypeptide 62a
NM-001929 DGUOK Deoxyguanosine kinase 61
NM-000162 GCK Glucokinase (hexokinase 4, maturity-onset diabetes of the young 2) 62
NM-153273 IHPK1 Inositol hexaphosphate kinase 1 55
NM-001569 IRAK1 Interleukin-1 receptor-associated kinase 1 59
XM-498294 LOC392265 Similar to cell-division protein kinase 5 (tau protein kinase II catalytic subunit) (TPKII catalytic subunit)
(serine/threonine-protein kinase PSSALRE)
67
NM-005922 MAP3K4 Mitogen-activated protein kinase kinase kinase 4 57
NM-015133 MAPK8IP3 Mitogen-activated protein kinase 8 interacting protein 3 56
NM-006206 PDGFRA Platelet-derived growth factor receptor, alpha polypeptide 63
NM-006212 PFKFB2 6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 60
NM-012395 PFTK1 PFTAIRE protein kinase 1 53
NM-000294 PHKG2 Phosphorylase kinase, gamma 2 (testis) 65
NM-018323 PI4K2B Phosphatidylinositol 4-kinase type-II beta 51a
NM-004570 PIK3C2G Phosphoinositide-3-kinase, class 2, gamma polypeptide 69a
NM-002651 PIK4CB Phosphatidylinositol 4-kinase, catalytic, beta polypeptide 56
NM-181805 PKIG Protein kinase (cAMP-dependent, catalytic) inhibitor gamma 65
NM-002658 PLAU Plasminogen activator, urokinase 57
NM-005030 PLK1 Polo-like kinase 1 (Drosophila) 86a
NM-006254 PRKCD Protein kinase C, delta 60
NM-016457 PRKD2 Protein kinase D2 60
NM-021135 RPS6KA2 Ribosomal protein S6 kinase, 90 kDa, polypeptide 2 50
NM-005983 SKP2 S-phase kinase-associated protein 2 (p45) 61
NM-003318 TTK TTK protein kinase 64
NM-031432 UCK1 Uridine-cytidine kinase 1 63
NM-006296 VRK2 Vaccinia-related kinase 2 55
aApoptosis is at least 5% more than the control for both siRNA sequences of the kinase, as measured by HCS system, based on nuclear properties (morphology
and Hoechst dye intensity) of the cells. Note: Growth inhibition resulted from siRNA silencing of SUM149 cells at 5 nM for 72 hours. Data shown here are the
average results of both siRNA sequences of the kinase from two independent screens. For a complete list of active kinases identified in the siRNA library screen,
refer to Additional file 1.
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PLK1 small-molecule inhibitor BI 2536 is as active as PLK1
siRNA against different breast cancer cell lines and TICs
and induces apoptosis
Like its siRNA counterpart, PLK1 small-molecule inhibitor
BI 2536 showed a significant growth-inhibitory effect on
the cells of the seven different breast cancer cell lines
under experimental conditions (Figure 4A). The active
concentrations are as low as 1 to 5 nM with 80% to 90%
growth reduction at 10 to 25 nM for most cancer cell lines
after a 72-hour treatment. In particular, HR5, a trastuzu-
mab-resistant cell line, is similarly sensitive to BI 2536 as
is BT474-M1. A longer period of treatment of SUM149
cells with BI 2536 killed almost all cells at concentrations
of 25 nM or higher (Figure 4B). More important, treat-
ment with BI 2536 significantly inhibited the growth of
sorted TICs of SUM149 compared with control (Figure
4C), further supporting its potential application in breast
cancer.
In mammosphere assays on both SUM149 and MDA-
MB-231 cells, BI 2536 treatment led to significant reduc-
tion of the sphere formation (Figure 4D). The results
further confirmed our earlier observation of the inhibitory
effect of BI 2536 on TICs on monolayer models.
Similar to PLK1 siRNA, BI 2536 also caused significant
apoptosis at 10 to 100 nM in all four cell lines tested, a
characteristic for PLK1 inhibition (Figure 4E through G).
The loss of PLK1 activity triggered apoptosis in up to
70% of BT474-M1 cells that remained at the end of the
72-hour treatment. SUM149 had relatively fewer cells left













































































































































































































































































































































































































































































































Figure 1 Growth inhibition of the 28 active kinases on different breast cancer cells after siRNA silencing. (A) Percentage growth
inhibition of SUM149 by the kinases after siRNA silencing at 5 nM for 72 hours. C, control without siRNA. *PLK1. (B) Percentage growth
inhibition of BT474-M1 by the kinases. (C) Percentage growth inhibition of MDA-MB-231 by the kinases. (D) Percentage growth inhibition of HR5
by the kinases. Data are presented as mean ± SD of two independent tests. Kinases in the figure: CDC2L1, cell-division cycle 2-like 1 (PITSLRE
proteins); CHEK1, CHK1 checkpoint homologue (S. pombe); CDC2, cell-division cycle 2, G1 to S and G2 to M; CSNK2A2, casein kinase 2, alpha prime
polypeptide; DGUOK, deoxyguanosine kinase; GCK, glucokinase (hexokinase 4, maturity-onset diabetes of the young 2); IRAK1, interleukin-1
receptor-associated kinase 1; MAP3K4, mitogen-activated protein kinase kinase kinase 4; PDGFRA, platelet-derived growth factor receptor, a
polypeptide; PFKFB2, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2; PIK3C2G, phosphoinositide-3-kinase, class 2, g polypeptide; PIK4CB,
phosphatidylinositol 4-kinase, catalytic, b polypeptide; PHKG2, phosphorylase kinase, g 2 (testis); PFTK1, PFTAIRE protein kinase 1; PLAU,
plasminogen activator, urokinase; PLK1, polo-like kinase 1 (Drosophila); PRKCD, protein kinase C, delta; SKP2, S-phase kinase-associated protein 2
(p45); RPS6KA2, ribosomal protein S6 kinase, 90 kDa, polypeptide 2; TTK, TTK protein kinase; VRK2, vaccinia-related kinase 2; IHPK1, inositol
hexaphosphate kinase 1; PKIG, protein kinase (cAMP-dependent, catalytic) inhibitor g; MAPK8IP3, mitogen-activated protein kinase 8 interacting
protein 3; PRKD2, protein kinase D2; PI4K2B, phosphatidylinositol 4-kinase type-II b; UCK1, uridine-cytidine kinase 1; LOC392265, similar to cell-
division protein kinase 5 (Tau protein kinase II catalytic subunit) (TPKII catalytic subunit) (serine/threonine-protein kinase PSSALRE).
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Figure 2 Effect of the active kinases on CD44high and the sorted CD44high/CD24-/low populations of SUM149. (A) Number of CD44high
cells (per view field, ×10 magnification) of SUM149 after kinase silencing by siRNA at 5 nM for 72 hours. C, control without siRNA; Sc, scramble
siRNA. *PLK1. (B) Growth inhibition of the sorted CD44high/CD24-/low population of SUM149 by siRNA silencing of different kinases at 5 nM for 72
hours. Data are presented as mean ± SD of two independent tests. Kinases in the figure: CDC2L1, cell-division cycle 2-like 1 (PITSLRE proteins);
CHEK1, CHK1 checkpoint homologue (S. pombe); CDC2, cell-division cycle 2, G1 to S and G2 to M; CSNK2A2, casein kinase 2, alpha prime
polypeptide; DGUOK, deoxyguanosine kinase; GCK, glucokinase (hexokinase 4, maturity-onset diabetes of the young 2); IRAK1, interleukin-1
receptor-associated kinase 1; MAP3K4, alpha mitogen-activated protein kinase kinase kinase 4; PDGFRA, platelet-derived growth factor receptor,
alpha polypeptide; PFKFB2, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2; PIK3C2G, phosphoinositide-3-kinase, class 2, gamma
polypeptide; PIK4CB, phosphatidylinositol 4-kinase, catalytic, beta polypeptide; PHKG2, phosphorylase kinase, gamma 2 (testis); PFTK1, PFTAIRE
protein kinase 1; PLAU, plasminogen activator, urokinase; PLK1, polo-like kinase 1 (Drosophila); PRKCD, protein kinase C, delta; SKP2: S-phase kinase-
associated protein 2 (p45); RPS6KA2, ribosomal protein S6 kinase, 90 kDa, polypeptide 2; TTK, TTK protein kinase; VRK2, vaccinia-related kinase 2;
IHPK1, inositol hexaphosphate kinase 1; PKIG, protein kinase (cAMP-dependent, catalytic) inhibitor gamma; MAPK8IP3, mitogen-activated protein
kinase 8-interacting protein 3; PRKD2, protein kinase D2; PI4K2B, phosphatidylinositol 4-kinase type-II beta; UCK1, uridine-cytidine kinase 1;
LOC392265, similar to cell-division protein kinase 5 (tau protein kinase II catalytic subunit) (TPKII catalytic subunit) (serine/threonine-protein kinase
PSSALRE).
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with the other three cell lines, probably because the mass
apoptosis occurred earlier. This was confirmed by time-
course experiments at earlier times (Figure 4F), in which
apoptosis peaked at about 48 hours after BI 2536 treat-
ments. Together, the results from nuclear morphology
(nuclear fragmentation and/or condensation), phospho-
H2AX detection (an earlier indicator of apoptosis), and
PI uptake (a late apoptosis indicator) clearly demon-
strated the apoptosis in breast cancer cells caused by BI
2536.
An unfortunate consequence of chemotherapies used
to treat breast cancer is that they induce TICs [15,17].
Here we show that Taxol, Dox, and 5FU inhibited can-
cer cell growth, while at the same time, they induced a
higher proportion of CD44high/CD24-/low cells from
about 2% in the controls to about 6% to 20% in the sur-
viving populations after a 72-hour exposure (Figure 5A
and 5B). After the induction of CD44high/CD24-/low cells
by these drugs, we subsequently exposed the cells to BI
2536 for an additional 4 days. The sequential treatment
led to almost complete cell death (Figure 5C). This
demonstrates that although resistant cells exist after the
drug treatments, they remain sensitive to BI 2536 at low
concentration. Most important, BI 2536 can be used to
overcome chemotherapy-induced TICs and suggested a
potential to prevent relapse.
Discussion
The key functions of kinases in signal transduction for
all organisms make them very attractive targets for ther-
apeutic interventions in many diseases, including can-
cers [18,21,23]. Several kinase inhibitors have been used
for the treatment of cancer, such as imatinib, gefitinib,
erlotinib, fasudil, and rapamycin [21,22]. Genome-wide
gene-library screens have proved an excellent tool in




























































































































Figure 3 PLK1 expression, its association with CD44, and its activity after BI 2536 inhibition. (A) PLK1 expression in different breast
cancer cells by immunoblotting. (B) PLK1 expression after PLK1 siRNA silencing in two TNBC (triple-negative breast cancer) cell lines, SUM149
and MDA-MB-231. (C) PLK1 is positively associated with CD44 expression with immunofluorescent assay. (D) Immunofluorescent images showing
the accumulation of phospho-cyclin B1 in SUM149 cells after BI 2536 treatment (72 hours). DMSO, dimethyl sulfoxide; DAPI, 4ʹ,6-diamidino-2-
phenylindole. (E) Quantitative analysis of phospho-cyclin B1 in SUM149 cells after BI 2536 treatment (72 hours).
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Figure 4 Effect of PLK1 inhibition on breast cancer cell growth, apoptosis, and TICs. (A) Percentage of growth inhibition of different
breast cancer cells by a PLK1 small-molecule inhibitor BI 2536 at different concentrations for 72 hours. C, control (medium only). D, dimethyl
sulfoxide only. (B) Percentage of growth inhibition of SUM149 cells by BI 2536 at different concentrations for 10 days. (C) Percentage of growth
inhibition of sorted CD44high/CD24-/low of SUM149 by BI 2536 for 72 hours. (D) Percentage of mammosphere reduction in SUM149 and MDA-
MB-231 by BI 2536. *Significant difference from the control (Student t test, P < 0.05). (E) Percentage of apoptosis of different breast cancer cells
caused by BI 2536 after 72 hours. (F) Time-course apoptosis of SUM149 treated with BI 2536 for 6, 24, and 48 hours. (G) Apoptotic images of the
cells after BI 2536 treatment, as revealed by HCS (high-content screening) instrument (×10) with phospho-H2AX antibody or PI (propidium
iodide) intake. Data are presented as mean ± SD of two independent tests. TICs, tumor-initiating cells.
Hu et al. Breast Cancer Research 2012, 14:R22
http://breast-cancer-research.com/content/14/1/R22




BI 2536 25 nM 
















































































Figure 5 Effect of combined treatment of Taxol, Dox, or 5FU followed by BI 2536 on SUM149 cells. (A) Taxol, Dox, and 5FU inhibited the
growth of SUM149 after 72 hours. C, control (medium only). (B) Drug treatment led to a higher percentage of CD44high/CD24-/low TIC (tumor-
initiating cell) subpopulation in surviving SUM149 cells after 72 hours. Top image panel: CD44high/CD24-/low cells (arrows) after 5FU treatment (0.1
mM, 72 hours) as viewed by HCS (high-content screening) instrument (×10). (C) Combined treatment with the drugs (Taxol, Dox, or 5FU) for 72
hours, followed by BI 2536 for another 96 hours, significantly reduced cell growth, even though the drugs induced a higher percentage of the
CD44high/CD24-/low subpopulation. All data are presented as mean ± SD of two independent tests. DMSO, dimethyl sulfoxide; Taxol, paclitaxel;
Dox, doxorubicin; 5FU, 5-fluorouracil.
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study, we screened a human kinase siRNA library
against a TNBC cell line, SUM149, for in vitro growth
inhibition. As a result, 85 kinases, including PLK1, were
identified to be strongly inhibitory against the cell
growth once they were silenced by corresponding siR-
NAs. The diverse functional groups of the kinases iden-
tified in this study demonstrate their important roles in
regulating the growth of breast cancer cells. In particu-
lar, about one fourth of the identified kinases were pre-
viously proposed to be the targets or already are in
clinical trials for breast cancers (Additional file 1).
AURKB, BUB1B, CHEK1, EPHB6, GSK3, MAPKs,
MYLK, NEKs, PDGFRA, PLAU, PLK1, PKC, RSK, SKP2,
and TTK are just a few of them [21,22,34-38]. Kinases
BUB1, CHEK1, IRAK1, TTK, RYK, and VRK2, identified
in this study, for example, have been reported to be
highly overexpressed in ER-negative breast tumors and
were critical for the growth of either ER-negative only
or both ER-positive and -negative breast cancer cells
[9,23]. These studies validate our approach of a gen-
ome-wide gene library screen in target discovery for
TNBC. In addition, most of the 28 active kinases that
were selected for further study showed a broad spec-
trum of activity, not only on TNBC, but also on other
ER/HER2-positive breast cancer groups. Thus our study
provides a broad basis of potential therapeutic targets,
not only to TNBC, but also to other subtypes of breast
cancers.
Cancer relapse has long been a clinical problem in breast
cancer treatment. Recent theories and evidence have
pointed to cancer stem cells or TICs for the root cause.
The cancer stem cell hypothesis proposed that tumors are
driven by a cellular component that retains stem cell prop-
erties, including self-renewal, tumorigenicity, and multili-
neage differentiation capacity [11,12]. In breast cancer,
several subpopulations, such as CD44high/CD24-/low,
CD133/PROM/prominin, and ALDEFLUOR+, have been
shown to contain highly enriched cancer stem cells
[10,15,39]. Targeting such a subpopulation, as well as the
bulk cancer population, could lead to complete cure of the
cancer diseases. In this study, after identifying the active
kinases, we questioned whether any of these kinases had
also played a role in TICs. When we analyzed the
CD44high population in the surviving cells after siRNA
treatment, 12 of these 28 selected kinases significantly
reduced the population of CD44high cells. This led to the
test of these 12 kinases directly against a sorted CD44high/
CD24-/low subpopulation of SUM149. As expected, they
inhibited the growth of the sorted TICs. The confirmation
of the anti-TIC subpopulation is particularly significant,
given the accepted role of TICs in drug resistance and
cancer relapse. The involvement of kinases in TICs of dif-
ferent cancers has been reported [16,25-27], and our study
provides new evidence for further exploration on these
kinases and TICs, in particular, for better breast cancer
therapy.
PLK1 is one of the four mammalian PLK family mem-
bers. Its prime role in mammalian cells is the control of
mitotic progression, particularly the regulation of proteins
that are involved in metaphase-anaphase transition and
mitotic exit. The activity and concentration of this kinase
are crucial for the precise regulation of cell division [40].
PLK1 was reported to be overexpressed in a broad spec-
trum of cancer types, and its expression often correlates
with poor patient prognosis [19,40,41]. PLK1 has long
been established as a marker for cellular proliferation [42].
Its levels in non-small-cell lung cancer tumors correlate
inversely with survival, indicating that PLK1 may have
prognostic value [43]. This was later confirmed in multiple
cancer types [40]. PLK1 expression has also been shown
to be a reliable marker for identifying a high risk of metas-
tasis in malignant melanomas [44]. In a cluster analysis of
82 normal and malignant breast specimens with cDNA
array, PLK1 was found overexpressed to various extents in
a subgroup of patient tumors, designated class A, which
contains a higher proportion of patients with metastases
and a greater risk of recurrence [45,46]. Given this, it
would be important to evaluate the potential for PLK1
inhibitors in patients with metastatic disease as a future
direction. Numerous studies have now established that
PLK1 is a prime target for drug development in prolifera-
tive diseases such as breast cancer [37,40]. Inhibition of
PLK1 leads to mitotic arrest, interruption of cytokinesis,
and apoptosis in susceptible tumor cell populations.
In this study, the expression of PLK1 in different breast
cancer subtypes was confirmed, and its inhibition led to
growth inhibition and apoptosis on all breast cancer cell
lines tested, indicating a broad application in breast can-
cer treatment. The sensitivity to PLK1 depletion has been
linked to p53 status in cancer cells, although conflicting
reports exist [19,40]. In this study, AU565 (ER- and
HER2+), which has a wild-type p53, is equally sensitive to
PLK1 inhibition as MDA-MB-231 (TNBC), which is p53
mutant. Similarly, of the three slightly less-sensitive cell
lines, SUM149 (TNBC) is p53 mutant, whereas MCF7
and T47D (ER+ and HER2-) are both p53 wt. The results
indicate that sensitivity to PLK1 inhibition may not be
linked directly to p53 status. Although a normal cell line
was not included in the study for comparison, numerous
studies, both in vivo and even clinical trials, have estab-
lished that PLK1 inhibition by siRNA or BI 2536 is well
tolerated, with neutropenia being the main side effect
[26,28,39,47-49]. PLK1 inhibitors seem also to have an
advantage over mitotic inhibitors such as the taxanes or
vinca alkaloids, because they do not induce the neuro-
toxicity, as do these earlier inhibitors [50,51]. Combina-
tion of PLK1 siRNA with chemotherapeutic drugs also
enhanced the sensitivity toward Taxol and trastuzumab
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(Herceptin) in a synergistic manner [32]. Most important,
our study represents the first attempt to associate PLK1
with TICs in breast cancer. Of the 28 selected kinases in
our focused studies, PLK1 is the leading candidate, based
on its activity in inhibiting cancer cell growth, and in par-
ticular, its activity against the TICs once silenced by
siRNA or by the small-molecule inhibitor, BI 2536. Fill-
more and Kuperwasser [15] reported that current che-
motherapeutic agents for breast cancer, such as Taxol
and 5FU, actually induced TICs. This is indeed the case
for Taxol, Dox, and 5FU, under our test conditions. In
addition, when these drug treatments were followed with
BI 2536, few cells survived, even though they induced
CD44high/CD24-/low cells under the experimental condi-
tions. Interestingly, Gleixner et al. [52] recently reported
that inhibiting PLK1 with BI 2536 could override imati-
nib resistance in chronic myeloid leukemia. Whether this
is related to the activity of PLK1 on TICs of the disease
remains to be explored.
Although PLK1 is the focus of our study for its signifi-
cant growth inhibition on breast cancer, availability of
small-molecular inhibitors, and the safety data in clinical
trials of different cancer treatment [28,40,49], several
other active kinases identified in this study deserve
further study for their roles in TICs in breast cancer,
such as SKP2 and PLAU (uPA), which inhibited the
growth of sorted CD44high/CD24-/low cells of SUM149.
Indeed, uPA/PAI-1 is the only biomarker to have been
conferred with LOE-1 as a definitive prognostic marker
of poor disease outcome in early breast cancer [53].
Furthermore, the guidelines of the American Society of
Clinical Oncology also consider the components of the
uPAS to be promising targets for future therapeutic stu-
dies [53]. The first inhibitors of uPA have now been
tested in oncology trials worldwide, and one of the com-
pounds, WX-671, has received US FDA approval for a
phase II trial in metastatic breast cancer in combination
with chemotherapy [53,54]. Evidence exists that uPA is
highly expressed in CD44+ cells [55]. Conceptually, this
fits with the idea that TICs are invasive [12], and as
such, they are found in circulating tumor cells from
patients [56]. High levels of uPA are also associated
with breast cancer relapse, which again could underpin
the idea that its expression in TICs is associated with
drug resistance. SKP2 is overexpressed in a subset of
breast carcinomas (ER- and HER2-) and might play a
role in the development of resistance to anti-estrogens
[34]. Overexpression of SKP2 is associated with resis-
tance to preoperative doxorubicin-based chemotherapy
in primary breast cancer [36]. Further confirmation of
this effect on TICs could help define better therapeutic
strategies. It should be noted also that our primary
screen targets the overall growth inhibition of SUM149
rather than the TICs; it is possible that some kinases
could be missed from the hit list if they are active only
on the TICs, but not or weakly active on the bulk of the
cancer cell population.
Conclusions
The inhibition of PLK1 led to significant growth inhibi-
tion, either alone or in combination with other drugs,
on different breast cancer cells and TICs, making them
promising therapeutic targets in the treatment of TNBC
and other breast cancers.
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